Kezar Life Sciences
4000 Shoreline Ct
Suite 300
South San Francisco
94080
United States
Tel: 650-822-5600
Website: http://www.kezarlifesciences.com/
Email: contact@kezarbio.com
107 articles about Kezar Life Sciences
-
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
3/14/2024
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
-
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
2/28/2024
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference.
-
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
2/26/2024
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
-
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/21/2023
Kezar Life Sciences, Inc. (Nasdaq: KZR) today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL.
-
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
11/13/2023
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - November 03, 2023
11/3/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 50,000 shares of its common stock with an exercise price of $0.77 per share, the closing price of Kezar’s common stock on November 1, 2023, the grant date of the award.
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - October 09, 2023
10/9/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 18,000 shares of its common stock with an exercise price of $1.15 per share, which is equal to the closing price of Kezar’s common stock on October 2, 2023, the grant date of the award.
-
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
10/3/2023
Kezar Life Sciences, Inc. announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs.
-
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
9/20/2023
Kezar Life Sciences, Inc. announced that it entered into a collaboration and license agreement with Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, to develop and commercialize zetomipzomib, Kezar’s novel, first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea and Southeast Asia.
-
Kezar Life Sciences to Participate in Three Upcoming September 2023 Investor Conferences
8/31/2023
Kezar Life Sciences, Inc. announced that the Company will participate in three upcoming investor conferences taking place in September.
-
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 04, 2023
8/4/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 66,000 shares of its common stock with an exercise price of $2.19 per share, which is equal to the closing price of Kezar’s common stock on August 1, 2023, the grant date of the awards.
-
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2023
7/7/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 6,000 shares of its common stock with an exercise price of $2.44 per share, which is equal to the closing price of Kezar’s common stock on July 5, 2023, the grant date of the award.
-
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 09, 2023
6/9/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 308,000 shares of its common stock with an exercise price of $3.06 per share, which is equal to the closing price of Kezar’s common stock on June 6, 2023, the grant date of the awards.
-
Kezar Life Sciences to Participate in the Jefferies Healthcare Conference
5/31/2023
Kezar Life Sciences, Inc today announced that John Fowler, Co-Founder and Chief Executive Officer, and Noreen R. Henig, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 2:00 pm ET in New York, NY.
-
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update.
-
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 05, 2023
4/5/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase 232,000 shares of its common stock with an exercise price of $3.05 per share, which is equal to the closing price of Kezar’s common stock on April 3, 2023, the grant date of the awards.
-
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
3/14/2023
Kezar Life Sciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.
-
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
3/13/2023
Kezar Life Sciences, Inc. today announced that the Company will pull forward its virtual Research and Development Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.
-
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
3/6/2023
Kezar Life Sciences, Inc. today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.
-
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 03, 2023
3/3/2023
Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase 33,000 shares of its common stock with an exercise price of $5.43 per share, which is equal to the closing price of Kezar’s common stock on March 2, 2023, the grant date of the awards.